Abstract
Aims and background:
There are only limited data on the safety and efficacy of panitumumab in patients who experienced severe infusion reactions during cetuximab antibody therapy.
Case report:
We report the case of a 69-year-old woman with chemotherapy-refractory metastatic colorectal cancer who received single-agent cetuximab treatment but experienced a severe reaction during the first infusion, despite premedication with corticosteroids/antihistamines. Cetuximab was discontinued and treatment with panitumumab initiated approximately 14 days later (without premedication); no infusion reactions occurred and there was a rapid improvement in her general condition. She experienced a partial response that was sustained for 7 months before progression.
Conclusions:
This case supports the use of panitumumab in patients with chemotherapy-refractory metastatic colorectal cancer and suggests that panitumumab may be used in some patients with prior infusion reactions to cetuximab.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Antibodies, Monoclonal / administration & dosage*
-
Antibodies, Monoclonal / adverse effects*
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents / administration & dosage*
-
Antineoplastic Agents / adverse effects*
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Camptothecin / administration & dosage
-
Camptothecin / analogs & derivatives
-
Cetuximab
-
Colorectal Neoplasms / diagnostic imaging
-
Colorectal Neoplasms / drug therapy*
-
Disease Progression
-
Disease-Free Survival
-
Drug Resistance, Neoplasm
-
Female
-
Fluorouracil / administration & dosage
-
Humans
-
Infusions, Intravenous
-
Leucovorin / administration & dosage
-
Organoplatinum Compounds / administration & dosage
-
Panitumumab
-
Tomography, X-Ray Computed
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Organoplatinum Compounds
-
Panitumumab
-
Cetuximab
-
Leucovorin
-
Fluorouracil
-
Camptothecin
Supplementary concepts
-
Folfox protocol
-
IFL protocol